Background: Laboratory work is associated with exposure to a mixture of carcinogens.
Methods: The cohort is comprised of 4,300 laboratory workers. Cancer incidence was followed from 1960 to 1997.
Results: A total of 230 cases were included in the cohort. The overall cancer standardized incidence ratio (SIR) was 1.04 (0.91-1.18). When a 20-year latency was introduced, SIR was increased significantly: 1.35 (1.13-1.61). Among routine workers and researchers, SIR was elevated significantly for the total population and for women, when a 20-year latency was introduced. SIR was also elevated significantly in research, routine, bacteriology and virology, and isotope laboratories. With respect to specific sites, significantly increased SIR was observed in breast, ovary, and thyroid cancer among women; and prostate cancer, leukemia, and melanoma among men.
Conclusions: We suggest that work in research and biomedical laboratories might involve an increased risk of certain types of cancer. Am. J. Ind. Med. 44:600-610, 2003.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajim.10311 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oropharyngeal cancer incidence and trends in Brazil.
Cancer Epidemiol Biomarkers Prev
January 2025
A.C. Camargo Cancer Center, São Paulo, Brazil.
Background: Oropharyngeal cancer (OPC) incidence is rising globally, predominantly in high-income countries due to human papillomavirus (HPV) infection. However, further data on OPC incidence in Brazil is needed. The aim of this study was to estimate the incidence, trends, and predictions of OPC in Brazilian population-based cancer registries (PBCRs) by period, sex, and topography.
View Article and Find Full Text PDFExternal Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema.
JAMA Netw Open
January 2025
Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Importance: Secondary lymphedema is a common, harmful side effect of breast cancer treatment. Robust risk models that are externally validated are needed to facilitate clinical translation. A published risk model used 5 accessible clinical factors to predict the development of breast cancer-related lymphedema; this model included a patient's mammographic breast density as a novel predictive factor.
View Article and Find Full Text PDFCardiotoxic Effects Following CAR-T Cell Therapy: A Literature Review.
Curr Oncol Rep
January 2025
Department of Radiology, Albert Einstein College of Medicine and the Montefiore Medical Center, 111 East 210Th Street, Bronx, NY, 10461, USA.
Purpose Of Review: This paper reviewed the current literature on incidence, clinical manifestations, and risk factors of Chimeric Antigen Receptor T-cell (CAR-T) cardiotoxicity.
Recent Findings: CAR-T therapy has emerged as a groundbreaking treatment for hematological malignancies since FDA approval in 2017. CAR-T therapy is however associated with a few side effects, among which cardiotoxicity is of significant concern.
Causal role of ischemic heart disease in ovarian cancer subtypes.
Discov Oncol
January 2025
Department of Cardiovascular Medicine, Jiu Jiang NO.1 People's Hospital, Jiujiang, 332000, China.
Background: Ischemic heart disease (IHD) may share biological mechanisms with cancer, including ovarian cancer, through pathways such as chronic inflammation and oxidative stress. However, the relationship between IHD and ovarian cancer subtypes remains unclear. This study used Mendelian randomization (MR) to explore potential causal associations.
View Article and Find Full Text PDFRare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023.
Cancer Causes Control
January 2025
Office of Cancer Survivorship, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Purpose: Rare cancers are defined as those for which there are less than 15 cases per 100,000 in the population annually. While much progress in detection and treatment has been made over the past decade for many rare cancers, less progress has been made in understanding survivorship needs. The objective of this study was to characterize the National Institutes of Health (NIH) cancer survivorship grant portfolio focused on rare cancers and to identify gaps specific to this area of science.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!